Home / Products / Genome-edited Cells / C1GALT1 Knockout HEK293T Cell Line

C1GALT1 Knockout HEK293T Cell Line

Cat. No. ARG43761
Product Type:

In Stock Cell Lines

Species:

Homo sapiens (Human)

Tissue Source:

Kidney

Growth Properties:

Adherent

In stock
Request a Quote

Short Description 🔒

The C1GALT1 Knockout HEK293T Cell Line is a CRISPR/Cas9-edited knockout cell line derived from HEK293T embryonic kidney epithelial cells, featuring disruption of the C1GALT1 gene that encodes core 1 synthase (T-synthase). This model serves to investigate mucin-type O-glycan biosynthesis, as C1GALT1 knockout leads to accumulation of truncated Tn antigen on substrates such as MUC1, integrins, and E-cadherin, and is regulated by the COSMC chaperone and transcription factor SP1. Widely applicable in cancer biology, glycoproteomics, and O-glycosylation research, this cell line enables lectin blotting, flow cytometry, and functional assays to probe glycoprotein-mediated adhesion, signaling, and immune recognition. Its HEK293T background provides high transfection efficiency and supports complementation studies.

Product Details
Cell Engineering
Immortalization
Culture Conditions
Quality Control
Disclaimer

Product Details

Product Type:
In Stock Cell Lines
Species:
Homo sapiens (Human)
Tissue Source:
Kidney
Growth Mode:
Adherent
Age:
Fetus
Sex of Donor:
Female
Derived From Site:
Fetal kidney
Size/Quantity:
1 million
Shipping info:
Cryopreserved in vials and shipped on dry ice
Storage:
Liquid nitrogen (LN2)

Cell Engineering Information

Host Cell:
HEK293T
Gene Name:
C1GALT1
Gene Identifier:
NCBI Gene ID 56913

Immortalization Information

No immortalization information available.

Culture Conditions

Temperature:
37°C
Atmosphere:
5% CO₂

Quality Control

Mycoplasma testing:
Negative for mycoplasma through PCR analysis
Sterility testing:
The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

Disclaimer

Intended Use:
This product is intended for laboratory in vitro use only. It is not intended for diagnostic, therapeutic, or clinical applications.
Disclaimer:
Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability.
Usage:
By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use. This product is provided "AS IS".

Description 🔒

The C1GALT1 Knockout HEK293T Cell Line is a CRISPR/Cas9-mediated gene-disrupted derivative of the HEK293T human embryonic kidney epithelial cell line, designed for loss-of-function studies of core 1 synthase glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1. This knockout cell line enables interrogation of mucin-type O-glycan biosynthesis and the consequences of ablating core 1 O-glycan formation (T antigen). By eliminating C1GALT1, it allows dissection of O-glycosylation-dependent processes in a host background widely used for recombinant protein expression and viral production.

HEK293T cells originate from HEK293 cells, immortalized from primary human embryonic kidney cells with sheared adenovirus 5 DNA, and additionally express SV40 large T antigen for episomal replication of SV40 origin-containing plasmids. This adherent epithelial line is noted for high transfection efficiency, robust protein production, and utility in lentiviral/retroviral packaging, making it an optimal host for gene disruption and subsequent overexpression or rescue experiments.

C1GALT1 encodes T-synthase, which transfers galactose from UDP-galactose to N-acetylgalactosamine-O-Ser/Thr residues to form core 1 O-glycan (T antigen), a key step in extending mucin-type O-glycans beyond the Tn antigen. Its activity requires the specific chaperone COSMC and interaction with HSP90B1 (GRP94) in the endoplasmic reticulum, while SP1 transcriptionally regulates C1GALT1 expression. Knockout of C1GALT1 causes accumulation of Tn antigen on substrates such as mucins MUC1 and MUC16, integrins, receptor tyrosine kinases, and E-cadherin, disrupting glycoprotein stability, cell adhesion, and downstream signaling.

In the HEK293T context, C1GALT1 knockout provides a defined system to study how mucin-type O-glycosylation modulates glycoprotein trafficking, cell?Ccell/matrix interactions, and immune recognition. This model is particularly relevant in cancer biology, where aberrant O-glycosylation with Tn antigen expression drives tumor progression via altered adhesion and immune evasion, and also aids in investigating Tn syndrome and IgA nephropathy. HEK293T??s manipulability supports complementation with C1GALT1 mutants and COSMC co-expression to validate chaperone dependence.

Typical applications include lectin blotting with PNA and flow cytometry for Tn/T antigens, glycoproteomics by mass spectrometry, and functional assays such as cell adhesion, migration, immunoprecipitation, western blotting of glycosylated proteins, and RT-qPCR to confirm C1GALT1 disruption. The cell line is essential for dissecting glycosylation-dependent signaling in oncogenic contexts and for evaluating therapeutics targeting aberrant glycosylation. For further information or to discuss custom applications, please contact Ascent Research.